Anti-FCGRT therapeutic antibody (Pre-made Nipocalimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nipocalimab is a fully human, aglycosylated, effectorless immunoglobulin G1 (IgG) anti-FcRN antibody that functions to reduce the levels of other IgG antibodies in the blood, including the autoantibodies that cause gMG.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-378-1mg	1mg	3090
GMP-Bios-ab-378-10mg	10mg	21890
GMP-Bios-ab-378-100mg	100mg	148000
GMP-Bios-ab-378-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-FCGRT therapeutic antibody (Pre-made Nipocalimab biosimilar,Whole mAb)
INN Name	Nipocalimab
Target	FCGRT
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	5whk:HL/5whj:HL
Year Proposed	2019
Year Recommended	2020
Companies	Momenta
Conditions Approved	na
Conditions Active	Autoimmune haemolytic anaemia;Haemolytic disease of newborn;Myasthenia gravis
Conditions Discontinued	na
Development Tech	na